Limits...
Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

Ruilope LM - Vasc Health Risk Manag (2008)

Bottom Line: Guidelines recommend that many patients will require two or more antihypertensive agents from different classes.Combining an angiotensin II receptor blocker (ARB) with hydrochlorothiazide (HCTZ) has been shown in clinical studies to increase the antihypertensive efficacy of both agents compared with either agent alone.Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure.

View Article: PubMed Central - PubMed

Affiliation: Unidad de HipertensiĆ³n, Hospital 12 de Octubre, Madrid, Spain. ruilope@ad-hocbox.com

ABSTRACT
Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and treatment of hypertension continues to be a challenge. Guidelines recommend that many patients will require two or more antihypertensive agents from different classes. Combining an angiotensin II receptor blocker (ARB) with hydrochlorothiazide (HCTZ) has been shown in clinical studies to increase the antihypertensive efficacy of both agents compared with either agent alone. This review covers several clinical trials and aims to examine several aspects of the efficacy of the combination of olmesartan and HCTZ, including dose-responsiveness, long-term efficacy, goal rate achievement, and efficacy in patients with moderate to severe hypertension. The results presented here demonstrate that olmesartan is effective when added to HCTZ monotherapy or when HCTZ is added to olmesartan monotherapy, both over the short and long term. Moderate to severe hypertension responds well to olmesartan/HCTZ combination therapy, and the great majority of patients are able to achieve recommended blood pressure targets. Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure.

Show MeSH

Related in: MedlinePlus

Changes in mean (a) seated diastolic blood pressure (DBP) and (b) systolic blood pressurse (SBP) over the 52-week treatment period by group in the long-term cohort.Abbreviation: HCTZ, hydrochlorothiazide.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2663442&req=5

f3-vhrm-4-1237: Changes in mean (a) seated diastolic blood pressure (DBP) and (b) systolic blood pressurse (SBP) over the 52-week treatment period by group in the long-term cohort.Abbreviation: HCTZ, hydrochlorothiazide.

Mentions: Notable decreases from baseline to last visit were seen for all treatment responders, and, as seen in the 12-week double-blind phase of the study, these greater decreases were seen in the combination therapy groups than in the placebo or monotherapy groups (Figure 3). The between-group differences were greater for SBP than DBP, and this could be expected due to the fact that this cohort of patients was permitted to continue in the extension phase only if they were already treatment responders.


Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension.

Ruilope LM - Vasc Health Risk Manag (2008)

Changes in mean (a) seated diastolic blood pressure (DBP) and (b) systolic blood pressurse (SBP) over the 52-week treatment period by group in the long-term cohort.Abbreviation: HCTZ, hydrochlorothiazide.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2663442&req=5

f3-vhrm-4-1237: Changes in mean (a) seated diastolic blood pressure (DBP) and (b) systolic blood pressurse (SBP) over the 52-week treatment period by group in the long-term cohort.Abbreviation: HCTZ, hydrochlorothiazide.
Mentions: Notable decreases from baseline to last visit were seen for all treatment responders, and, as seen in the 12-week double-blind phase of the study, these greater decreases were seen in the combination therapy groups than in the placebo or monotherapy groups (Figure 3). The between-group differences were greater for SBP than DBP, and this could be expected due to the fact that this cohort of patients was permitted to continue in the extension phase only if they were already treatment responders.

Bottom Line: Guidelines recommend that many patients will require two or more antihypertensive agents from different classes.Combining an angiotensin II receptor blocker (ARB) with hydrochlorothiazide (HCTZ) has been shown in clinical studies to increase the antihypertensive efficacy of both agents compared with either agent alone.Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure.

View Article: PubMed Central - PubMed

Affiliation: Unidad de HipertensiĆ³n, Hospital 12 de Octubre, Madrid, Spain. ruilope@ad-hocbox.com

ABSTRACT
Hypertension is a major risk factor for cardiovascular disease that contributes to the premature death of millions of people each year, and identification and treatment of hypertension continues to be a challenge. Guidelines recommend that many patients will require two or more antihypertensive agents from different classes. Combining an angiotensin II receptor blocker (ARB) with hydrochlorothiazide (HCTZ) has been shown in clinical studies to increase the antihypertensive efficacy of both agents compared with either agent alone. This review covers several clinical trials and aims to examine several aspects of the efficacy of the combination of olmesartan and HCTZ, including dose-responsiveness, long-term efficacy, goal rate achievement, and efficacy in patients with moderate to severe hypertension. The results presented here demonstrate that olmesartan is effective when added to HCTZ monotherapy or when HCTZ is added to olmesartan monotherapy, both over the short and long term. Moderate to severe hypertension responds well to olmesartan/HCTZ combination therapy, and the great majority of patients are able to achieve recommended blood pressure targets. Thus olmesartan/HCTZ is a well-tolerated option for patients who fail to respond to monotherapy and as initial therapy in those who require large reductions in diastolic blood pressure or systolic blood pressure to achieve goal blood pressure.

Show MeSH
Related in: MedlinePlus